News and Media

Lidocaine-Tchaikapharma 10 mg and 20 mg solution for injection is Tchaikapharma’s newest product which has obtained a Marketing Authorization issued by the Bulgarian Drug Agency.

Therapeutic indications:

• For local anesthesia in surgery, dentistry, urology, cardiology, ophthalmology, otorhinolaryngology and other invasive instrumental investigations.
• For the treatment of ventricular arrhythmias, including after myocardial infarction and cardiac surgery interventions.

ATC code: C01BB 01, N01BB 02

The renowned business ranking “300 Business Leaders in Bulgaria” for one more year honoured Tchaikapharma High Quality Medicines Inc. as one of the most profitable and influential companies in Bulgaria.

The ranking’s fifth edition prepared by analysts from ICAP Group brings together the most successful companies in the country for the past year 2015, based on the criterion “Earnings before interest, taxes, depreciation and amortization (EBITDA)”.

This year Tchaikapharma marked alike a growth on the paramount indicators ‘profit’ (13%) and ‘equity’ (15%). In 2015, EBITDA-profit of the company rose by nearly 11% over the previous year.

These positive trends determine the high market capitalization of the company amounting to approximately 372.5 million leva (as of 21/11/2016).

The newest product of Tchaikapharma High Quality Medicines Inc., which BDA gave a marketing authorisation for, is Cilapenem 500 mg/500 mg powder for infusion solution.

Each phial contains the following active substances: 530 mg imipenem monohydrate, which is equivalent to 500 mg imipenem anhydrоus, and 532 mg cilastatin sodium, equivalent to 500 mg cilastatin.
The drug is indicated for the treatment of infections in adults and over 1 year-old children:

– Complicated intra-abdominal infections;

– Severe types of pneumonia, including nosocomial pneumonia and ventilator- associated pneumonia;
– Infections during and after birth;
– Complicated urinary tract infections;
– Complicated skin and soft tissue infections

Tsilapenem is also suitable for the treatment of patients with:
– Neutropenia and fever, suspected to be due to bacterial infection;
– Bacteraemia occurring in connection with or presumably associated with any of the above infections.

The medicinal product is subject to medical prescription.
ATC code: J01DH 51

The newest medicinal product placed on the market after having received a marketing authorization from the Bulgarian Drug Agency by the Ministry of Health is the infusion solution Linezolid-Tchaikapharma 2 mg/ml.
Its active substance is linezolid, and a packaging contents 300 ml x 5 pcs. or 10 pcs.
This medicinal product is used in cases of hospital- or community-acquired pneumonias, where they are known or suspected to be caused by sensitive Gram-positive bacteria.
Linezolid-Tchaikapharma is subject to medical prescription.

ATC code: J01XX 08